AZBio Members
05/17/2013Personalized Medicine
Leaders from across Greater Phoenix share what is happening here on the frontiers of personalized medicine and a unique gene found here in Arizona that gives us a distinct competitive advantage.
AZBio Members
05/17/2013Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches.Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award.
AZBio Members
05/29/2013ASU: A New American University
Fifty years of progress in one decade.
Arizona State University's President Michael Crow shares insight into how ASU has grown over the last 10 years and where it is going.
Learn more about ASU's strategy, Mission, and the Role that
AZBio Members
05/17/2013Choosing Arizona
A Global Perspective from executives of Arizona’s Bioscience Companies on why they are in Arizona
Panelists
- Bob Bosserman, CEO, Medelis
- Janet Spear, Plant Manager, Celgene
- Joan Koerber-Walker, president & CEO, AZBio (moderator)
- Dr. Ken Wertman, Scientific Director, Sanofi, Oro Valley
- Dr. Phil Miller, Ventana
AZBio Members
06/15/2013Cord Blood Stem Cell Partnerships
Partners for Progress in Cord Blood Stem Cell Research: Advocates, PhysicianResearchers and Industry Working Together
- Charis Ober, President – Save the Cord Foundation
- Joseph Miller, MD, MPH – Department Head,
AZBio Members
10/14/2013Leslie Boyer, MD 2013 Arizona Bioscience Researcher of the Year
In 2013, Dr. Leslie Boyer was been named one of 30 heroes of rare diseases by the Food and Drug Administration’s Office of Orphan Products Development. Her work includes a clinical studies program conducted throughout Arizona with protocols for placebo-controlled, double-blind trials, open-label studies, historical control studies, and the statewide STING project. She has coordinated phase 2 and phase 3 multicenter clinical trials of pit viper antivenom, developed the Antivenom Index, and participated in the establishment of the Pan-American Lymphotoxinology Taskforce. Boyer, who is a member of the UA’s BIO5 Institute, has focused her scientific career on venomous bites and stings, which are often unrecognized public health issues. She began by developing public education programs that offer poison and toxin emergency treatment advice. In 2004 and 2005, with an FDA Orphan Product grant, she led a team that conducted clinical studies leading to the marketing approval of the first scorpion antivenom – representing one of more than 40 products developed through orphan grant-sponsored research.
AZBio Members
05/17/20132012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day.Critical Path Institute, a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does.C-Path Milestones and “firsts” include:
- 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely.
- 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data.
- 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes.
- 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials.
- 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials.
AZBio Members
05/17/20132012 State of the Industry: John D. Carroll of FierceBiotech
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered virtually every aspect of the global drug development industry over the past decade. His work includes the popular Fierce 15, which recognizes the most innovative private companies in the business each year. His daily reports keep more than 100,000 subscribers around the world clued in to the latest developments on deals, data and industry trends. Carroll plans to address the biggest influences affecting the fast-changing biopharma industry and what it means to biotech executives in Arizona.
